Hong Kong IT Stock News

Minth Group (SEHK:425) has signed a framework agreement tied to AI robotics, signaling a push into intelligent automation that aligns with its role in automotive manufacturing and technology development. See our latest analysis for Minth Group. The AI robotics agreement lands at a time when momentum in Minth Group's shares is already strong, with a 27.86% 1 month share price return and a 162.82% 1 year total shareholder return, which points to building enthusiasm rather than fading...

What recent performance says about Cathay Pacific Airways (SEHK:293) Cathay Pacific Airways (SEHK:293) has drawn fresh attention after a 1 day return of about 1.8%, adding to gains over the past week, month, and past 3 months, and extending a 1 year total return above 35%. For context, the stock shows a 7 day return near 4.9%, around 1.8% over the past month, and roughly 5.7% over the past 3 months, with year to date performance close to 1.3%. See our latest analysis for Cathay Pacific...

Why Swire Pacific is on investors’ radar Swire Pacific (SEHK:19) has drawn attention after a strong run over the past month, with the share price moving in line with reported revenue of HK$88,180.0m and net income of HK$1,222.0m. See our latest analysis for Swire Pacific. That recent move comes on top of a 19.9% 30 day share price return and a 24.7% year to date gain, while the 1 year total shareholder return of 30.6% and 5 year total shareholder return of 135.95% indicate momentum that has...

Wanguo Gold Group (SEHK:3939) has drawn fresh attention after issuing 2025 earnings guidance that points to a very large profit uplift, alongside forming a new Strategic Development Committee packed with veteran mining executives. See our latest analysis for Wanguo Gold Group. These earnings targets and senior appointments come after a period of strong momentum, with the 30 day share price return of 53.93% and year to date share price return of 86.79% sitting alongside a very large 1 year...

Key Insights China Suntien Green Energy's estimated fair value is HK$4.48 based on Dividend Discount Model China...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

With a price-to-earnings (or "P/E") ratio of 7.5x The United Laboratories International Holdings Limited ( HKG:3933...

Earnings and dividend decision set the tone for Hang Lung Properties Hang Lung Properties (SEHK:101) has put investors' attention on its latest full year earnings, which showed lower sales and net income, alongside a recommended final cash dividend of HK$0.40 per share. See our latest analysis for Hang Lung Properties. Despite the softer full year earnings, Hang Lung Properties’ recent share price performance has been positive, with a 30 day share price return of 3.38% and an 8.72% share...

As the Asian markets navigate a landscape marked by global volatility and shifting investor sentiment, opportunities continue to emerge for those looking beyond traditional large-cap investments. Penny stocks, often associated with smaller or newer companies, remain an intriguing area of focus due to their potential for growth and affordability. While the term may seem outdated, these stocks can offer significant value when backed by strong financials, as demonstrated by the three noteworthy...

Unfortunately for some shareholders, the Sinohope Technology Holdings Limited ( HKG:1611 ) share price has dived 26% in...

There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...

Why Datang International Power Generation stock is in focus Datang International Power Generation (SEHK:991) issued preliminary 2025 guidance indicating net profit attributable to equity holders of about CN¥6.8b to CN¥7.8b, with net profit after non recurring items projected at CN¥7.2b to CN¥8.2b. See our latest analysis for Datang International Power Generation. The latest guidance and 2025 operating update land after a mixed period for the share price, with Datang International Power...

Key Insights Dongfang Electric's significant private companies ownership suggests that the key decisions are influenced...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Key Insights Laopu Gold's significant private companies ownership suggests that the key decisions are influenced by...

Key Insights The considerable ownership by private companies in China Resources Beer (Holdings) indicates that they...

As global markets navigate a period of volatility marked by concerns over artificial intelligence and geopolitical tensions, investors are increasingly turning their attention to Asia's growth potential. In this environment, stocks with high insider ownership can offer unique insights into companies' long-term prospects, as insiders often have a vested interest in the success of the businesses they help manage.

As Asian markets navigate a period of economic shifts and evolving investor sentiment, the focus has increasingly turned to the potential of smaller-cap stocks. Penny stocks, while often seen as remnants of past market eras, continue to offer intriguing opportunities for investors seeking growth at accessible price points. By examining those with strong financial foundations and clear growth potential, we can uncover compelling investment prospects within this often overlooked segment.

CARsgen Therapeutics Holdings (SEHK:2171) issued preliminary 2025 earnings guidance indicating a sharp year on year reduction in net loss, driven by commercial activity, lower research costs, and foreign exchange effects. See our latest analysis for CARsgen Therapeutics Holdings. CARsgen Therapeutics Holdings’ latest guidance lands after a volatile stretch, with a 6.32% 1 day share price return to HK$14.13 following recent weakness, including a 13.74% 30 day share price decline. The 1 year...

Why the TQA3605 trial update matters for Sino Biopharmaceutical Sino Biopharmaceutical (SEHK:1177) has drawn investor attention after reporting that its HBV candidate TQA3605 met the primary endpoint in a Phase II trial, combining with nucleos(t)ide analogues for chronic hepatitis B patients. The randomized, double blind, placebo controlled study enrolled 122 subjects and compared several TQA3605 dose groups with a nucleos(t)ide analogue only control arm. All active dose groups reached around...

Hangzhou SF Intra-city Industrial Co., Ltd. ( HKG:9699 ) shareholders would be excited to see that the share price has...

Digital Domain Holdings Limited ( HKG:547 ) shares have had a horrible month, losing 27% after a relatively good period...

When close to half the companies in Hong Kong have price-to-earnings ratios (or "P/E's") above 13x, you may consider...